{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:35:45Z","timestamp":1781706945740,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.seizure.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:03:18Z","timestamp":1693807398000},"page":"203-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety of brand name to generic substitution of lacosamide in patients with epilepsy - A prospective single-center observational study"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-5934","authenticated-orcid":false,"given":"Magdalena","family":"Bosak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-6001","authenticated-orcid":false,"given":"Martyna","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-1441","authenticated-orcid":false,"given":"Maciej","family":"Kasprzycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8261-537X","authenticated-orcid":false,"given":"Agnieszka","family":"S\u0142owik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2023.09.001_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5698\/1535-7511-16.3.209","article-title":"AES position statement on generic substitution of antiepileptic drugs","volume":"16","author":"Vossler","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2023.09.001_bib0002","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ana.25353","article-title":"Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: a nationwide study of prescription data in Germany","volume":"84","author":"Lang","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2023.09.001_bib0003","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.0b013e3181df091b","article-title":"Generic antiepileptic drugs and associated medical resource utilization in the United States","volume":"74","author":"Labiner","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2023.09.001_bib0004","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","article-title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","volume":"70","author":"LeLorier","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2023.09.001_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2017.03.012","article-title":"Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting","volume":"48","author":"Markoula","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.09.001_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eplepsyres.2019.02.017","article-title":"Brand-to-generic oxcarbazepine switch-a prospective observational study","volume":"151","author":"Bosak","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2023.09.001_bib0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomized controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2023.09.001_bib0008","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/ene.13568","article-title":"Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study","volume":"25","author":"Trimboli","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2023.09.001_bib0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.seizure.2018.06.020","article-title":"Brand name to generic substitution of levetiracetam in patients with epilepsy","volume":"60","author":"Gha-Hyun","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.09.001_bib0010","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/DDDT.S138270","article-title":"Safety of switching from brand-name to generic levetiracetam in patients with epilepsy","volume":"11","author":"Bosak","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.seizure.2023.09.001_bib0011","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jamaneurol.2017.0497","article-title":"Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial","volume":"74","author":"Berg","year":"2017","journal-title":"Jama Neurol"},{"key":"10.1016\/j.seizure.2023.09.001_bib0012","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.seizure.2021.05.011","article-title":"The times they are a-changin - Don\u00b4t panic with a generic!","volume":"91","author":"Kr\u00e4mer","year":"2021","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2023.09.001_bib0013","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40261-015-0351-1","article-title":"Safety of overnight switch from brand-name to generic levetiracetam","volume":"36","author":"Vari","year":"2016","journal-title":"Clin Drug Investig"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123002339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123002339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T10:55:19Z","timestamp":1728039319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123002339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":13,"alternative-id":["S1059131123002339"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.09.001","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of brand name to generic substitution of lacosamide in patients with epilepsy - A prospective single-center observational study","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}